{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T02:10:05Z","timestamp":1749089405331,"version":"3.41.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.xkme.2025.100967","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T18:56:39Z","timestamp":1737226599000},"page":"100967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Mediated Complete Remission of a PLA2R-Positive Paraneoplastic Membranous Nephropathy: A Case Report"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6369-4926","authenticated-orcid":false,"given":"Rayane","family":"Benyahia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Colombat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serigne","family":"Gueye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Mazi\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Belliere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.xkme.2025.100967_bib1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2025.100967_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2008.08.003","article-title":"Paraneoplastic glomerular diseases and malignancies","volume":"70","author":"Bacchetta","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.xkme.2025.100967_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad228","article-title":"Novel biomarkers and pathophysiology of membranous nephropathy: PLA2R and beyond","volume":"17","author":"Murtas","year":"2024","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.xkme.2025.100967_bib4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","article-title":"Absolute number of new lesions on 18F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab","volume":"45","author":"Anwar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.xkme.2025.100967_bib5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.xkme.2025.100967_bib6","first-page":"271","article-title":"Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases","volume":"31","author":"Radice","year":"2018","journal-title":"J\u00a0Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2025.100967_bib7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/1724600819882698","article-title":"Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review","volume":"34","author":"Zhang","year":"2019","journal-title":"Int J Biol Markers"},{"issue":"6","key":"10.1016\/j.xkme.2025.100967_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00428-019-02558-0","article-title":"Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy","volume":"474","author":"Hara","year":"2019","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.xkme.2025.100967_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.semnephrol.2010.09.011","article-title":"Membranous nephropathy and malignancy","volume":"30","author":"Beck","year":"2010","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2025.100967_bib10","first-page":"40","article-title":"PLA2R1: Expression and function in cancer","volume":"1846","author":"Bernard","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"18","key":"10.1016\/j.xkme.2025.100967_bib11","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2025.100967_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13730-020-00556-9","article-title":"Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma","volume":"10","author":"Yasuda","year":"2021","journal-title":"CEN Case Rep"},{"issue":"2","key":"10.1016\/j.xkme.2025.100967_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.xkme.2025.100967_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xkme.2025.100967_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.xkme.2025.100967_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/ph17020252","article-title":"Immune checkpoint inhibitors and lupus erythematosus","volume":"17","author":"Vitzthum von Eckstaedt","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"10.1016\/j.xkme.2025.100967_bib17","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ekir.2023.06.001","article-title":"Membranous nephropathy after exposure to immune checkpoint inhibitors","volume":"8","author":"Benyahia","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1016\/j.xkme.2025.100967_bib18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.xkme.2025.100967_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1197364","article-title":"Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases","volume":"14","author":"Ibis","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.xkme.2025.100967_bib20","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1007\/s00432-023-04582-9","article-title":"Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases","volume":"149","author":"Pizuorno Machado","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.xkme.2025.100967_bib21","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.xkme.2025.100967_bib22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2021.03.028","article-title":"A\u00a0conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy","volume":"100","author":"Lerner","year":"2021","journal-title":"Kidney Int"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T01:37:44Z","timestamp":1749087464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2590059525000032"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.100967","relation":{},"ISSN":["2590-0595"],"issn-type":[{"type":"print","value":"2590-0595"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-Mediated Complete Remission of a PLA2R-Positive Paraneoplastic Membranous Nephropathy: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.100967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100967"}}